Comparative Study of LoKomat® Exoskeleton VS C-Mill® Treadmill for Gait Recovery in Rehabi
The use of robotic technology for the treatment of gait in neurological pathologies has provided different results in scientific evidence. In patients with some types of acquired brain damage, such as stroke, the use of Lokomat® therapy can bring improvements in aspects such as gait speed and balance, among other param
| Condition(s) | Stroke |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The use of robotic technology for the treatment of gait in neurological pathologies has provided different results in scientific evidence. In patients with some types of acquired brain damage, such as stroke, the use of Lokomat® therapy can bring improvements in aspects such as gait speed and balance, among other parameters and report greater functional recovery in subacute patients with greater deterioration. Similarly, the use of another technological element such as the C-Mill® reports improvements in various aspects of ambulation and balance in gait treatments for stroke patients. Likewise, the impact on the person's recovery is not only beneficial for gait rehabilitation, but also improves the perception of well-being, which can be positive in the process of readaptation to daily life |
| Who can participate | Inclusion Criteria: * Diagnosis of stroke (haemorrhagic and/or ischaemic) by a specialist physician. . * Subjects who are cognitively capable and who sign the informed consent form. Exclusion Criteria: * Severe cognitive impairment (Mini-Mental State Examination \< 24.), or impairment that prevents correct understanding of the correct understanding of the messages and explanatory orders of the treatment and its conditions. * Diagnosis of concomitant neurological diseases and craniocerebral trauma. cranioencephalic trauma. * Other diseases that interfere with the gait process (e.g. disabling arthritis or arthrosis, other neurological diseases, other neurological diseases). disabling arthritis or osteoarthritis, other concomitant neurological diseases, etc.). \- Contraindications of the robo |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Universidad Pontificia de Salamanca |
| Locations | Salamanca, Spain |
| Start date | 2025-12-09 |
| NCT ID | NCT07230470 |
| Official listing | https://clinicaltrials.gov/study/NCT07230470 |